AMENDED AND RESTATED TECHNOLOGY LICENSE AND SERVICES AGREEMENT by and between NEUROTROPE BIOSCIENCE, INC., on the one hand, and BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE and NRV II, LLC, on the other hand, dated February 4, 2015Technology License and Services Agreement • February 10th, 2015 • Neurotrope, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 10th, 2015 Company Industry JurisdictionThis Amended and Restated Technology License and Services Agreement is made and entered into as of February 4, 2015 by and between Neurotrope BioScience, Inc., a corporation organized and existing under the laws of Delaware (“Neurotrope”), on the one hand, and Blanchette Rockefeller Neurosciences Institute, a not-for-profit institution organized and existing under the laws of the State of West Virginia (“BRNI”), and NRV II, LLC, a limited liability company organized and existing under the laws of the State of Delaware (“NRV II”), on the other hand. Neurotrope, BRNI and NRV II are sometimes referred to herein, individually, as a “Party” or, collectively, as the “Parties.”
Statement of Work and Account Satisfaction AgreementAccount Satisfaction Agreement • February 10th, 2015 • Neurotrope, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 10th, 2015 Company IndustryThis Statement of Work and Account Satisfaction Agreement (“SOW Agreement”) is made and entered into on February 4, 2015 by and between Neurotrope Bioscience, Inc. (“NTRP” or “Neurotrope”) and Blanchette Rockefeller Neurosciences Institute (“BRNI”) (each, a “Party” and collectively, the “Parties”), and is effective as of October 1, 2014 (the “SOW Agreement Effective Date”), pursuant to that certain Technology License and Services Agreement dated October 31, 2012 by and between NTRP, on the one hand, and BRNI and NRV II LLC, on the other hand, as amended by Amendment No. 1 to the Technology License and Services Agreement dated August 21, 2013, and as further amended and restated as of February 4, 2015 (the “TLSA”). This SOW Agreement hereby incorporates, and is subject to, the terms and conditions of the TLSA. All capitalized terms used herein but not defined herein shall have the respective meanings ascribed to them in the TLSA.
CONVERSION AGREEMENTConversion Agreement • February 10th, 2015 • Neurotrope, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 10th, 2015 Company IndustryTHIS CONVERSION AGREEMENT (this “Agreement”), dated as of _________, 2015 (the “Effective Date”), is by and between the undersigned Series A Preferred Stock Purchase Warrant holder (the “Holder”) and Neurotrope, Inc., a Nevada corporation (the “Company”). The Company and the Stockholder will sometimes hereinafter be referred to collectively as the “Parties” or each, individually, as a “Party.”